

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Date This Paper Filed : May 16, 2001

Complete if Known

Application Number	Not Known
Filing Date	May 16, 2001
First Named Inventor	OSANAI et al.
Group Art Unit	Not Known 1644
Examiner Name	Not Known NDLAN
Attorney Docket Number	46220
Sheet 1 of 1	

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PV	AR	5,849,527		Incyte Pharmaceuticals	12-15-1998	
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					
	JR					
	KR					

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Inventor Name	Document Number	Country	Date of Publication of Cited Document MM-DD-YYYY	English Abstract		Translation Readily Available	
						Encl	No	Encl	No
	LR								
	MR								
	NR								
	OR								

OTHER (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages)

PV	RR	Osanai et al. A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats, J. Biol Chem, 1998, pp 31778-83		
I	SR	Ando et al. Differential display and cloning of shear stress-responsive messenger RNAs in human endothelial cells, Biochem & Biophys Res Comm, 1996, pp 347-51		
↓	TR	Evans et al. An import-competent precursor of small subunit of ribulose-1,5-bisphosphate carboxylase generated by factor Xa cleavage from a beta-galactosidase fusion expressed in Escherichia coli, Protein Expr Purif, 1992, pp 178-84		

Examiner Signature	<i>Paul L. M...</i>	Date Considered	7/22/05
--------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Date This Paper Filed : May 16, 2001

Sheet	1	of	1	Attorney Docket Number	46220
-------	---	----	---	------------------------	-------

## Complete if Known

Application Number	Not Known
Filing Date	May 16, 2001
First Named Inventor	OSANAI et al.
Group Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	46220

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AR	5 849 527		Incyte Pharmaceuticals	12-15-1998	
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	JR					
	JR					
	KR					

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Inventor Name	Document Number	Country	Date of Publication of Cited Document MM-DD-YYYY	English Abstract		Translation Readily Available	
						End	No	End	No
	LR								
	MR								
	NR								
	OR								

## OTHER (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages)

RR	Osanai et al. A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats, J. Biol Chem, 1998, pp 31778-83		
SR	Ando et al, Differential display and cloning of shear stress-responsive messenger RNAs in human endothelial cells, Biochem & Biophys Res Comm, 1996, pp 347-51		
TR	Evans et al, An import-competent precursor of small subunit of ribulose-1,5-bisphosphate carboxylase generated by factor Xa cleavage from a beta-galactosidase fusion expressed in Escherichia coli, Protein Expr Purif, 1992, pp 178-84		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.